CARNITOR (levocarnitine) by Leadiant Biosciences is clinical pharmacology carnitor (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. First approved in 1985.
Drug data last refreshed 13h ago · AI intelligence enriched Yesterday
CARNITOR (levocarnitine) is a naturally occurring carnitine analog that facilitates long-chain fatty acid entry into mitochondria for energy production. It is indicated for primary and secondary carnitine deficiency, including inborn errors of metabolism such as glutaric aciduria II, methylmalonic aciduria, propionic acidemia, and medium-chain fatty acyl-CoA dehydrogenase deficiency. The drug works by promoting excretion of toxic acylCoA compounds that accumulate in these metabolic disorders, preventing life-threatening acidosis.
Product approaching loss of exclusivity with low competitive pressure; commercial teams should expect declining market share and smaller team footprint.
CLINICAL PHARMACOLOGY CARNITOR (levocarnitine) is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids…
Worked on CARNITOR at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Carnitine Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCARNITOR offers limited career growth opportunity given approaching LOE and zero linked job openings; roles focus on rare disease expertise and metabolic disorder management rather than high-volume sales. Working on this product develops deep pharmacology and orphan disease acumen but provides constrained advancement potential.